A
ggregatibacter actinomycetemcomitans is a Gram-negative organism that is associated with aggressive forms of periodontitis and other systemic infections (1) (2) (3) (4) (5) . Periodontitis is a chronic infectious inflammatory disorder that ultimately leads to the destruction of tooth-supporting tissue. While the exact nature of the pathogenesis of periodontal disease and the contribution of bacteria to this process are not known, it is becoming increasingly clear that A. actinomycetemcomitans produces several potential virulence factors; these include adhesins and fimbria which have been shown to contribute to colonization of the human oral cavity as well as two exotoxins, cytolethal distending toxin (Cdt) and leukotoxin, both of which are capable of killing and/or altering the function of host immune cells (4, (6) (7) (8) .
The Cdts are a family of heat-labile protein cytotoxins produced by several additional bacterial species, including Campylobacter jejuni, Shigella species, Haemophilus ducreyi, and diarrheal disease-causing enteropathogens such as some Escherichia coli isolates (9) (10) (11) (12) (13) (14) (15) . There is clear evidence that Cdts are encoded by three genes, designated cdtA, cdtB, and cdtC, which are arranged as an apparent operon (7, (15) (16) (17) (18) (19) (20) . The Cdt holotoxin consists of three subunits, CdtA, CdtB, and CdtC, that form a heterotrimeric complex. Furthermore, there is considerable agreement among investigators that, regardless of the microbial source of Cdt, the heterotrimeric holotoxin functions as an AB 2 toxin where CdtB is the active (A) unit and the complex of CdtA and CdtC comprises the binding (B) unit (18, 21, 22) . Indeed, several investigators have demonstrated that the internalization of CdtB requires the presence of both CdtA and CdtC (21, 23, 24) .
While several cell types and cell lines have been shown to be susceptible to the toxic actions of Cdt, tropism for specific cells and/or tissue remains to be identified. In this regard, we have demonstrated that lymphocytes in vitro are most susceptible, requiring very low concentrations of Cdt (picograms/milliliter) to induce cell cycle arrest and apoptosis versus other cell types that typically require as much as microgram quantities (25) . Typically, susceptibility to bacterial toxins is dependent upon the expression of specific receptors or moieties that enable the toxin to preferentially associate with target host cells. Structural analysis of CdtA and CdtC identified ricin-like lectin domains, suggesting that these units interact with cell surface carbohydrate moieties (18) . Several investigators have further demonstrated that, depending on the Cdt source, toxin binding to target cells was dependent upon cell surface N-linked glycoproteins, fucose, glycans, or glycosphingolipid (26, 27) .
In previous studies we have demonstrated that A. actinomycetemcomitans Cdt subunits CdtA and CdtC are not only required for the toxin to associate with lymphocytes but also responsible for localizing the toxin to lipid membrane microdomains (28, 29) . Furthermore, Cdt-mediated toxicity was found to be dependent upon the integrity of these lipid domains. Previously, we demonstrated that toxin association with lymphocytes, delivery of CdtB to intracellular targets, and the induction of both cell cycle arrest and apoptosis were dependent upon cholesterol (29) . Specifically, we have shown that the CdtC subunit contains a cholesterol recognition amino acid consensus (CRAC) site that binds to cholesterol in the context of lipid membrane microdomains. More recently, other investigators have also demonstrated CRAC sites on Cdt produced by Haemophilus parasuis and C. jejuni (30, 31) . We now report that in addition to CdtC, the active subunit CdtB also contains a CRAC site that is required for its internalization and the induction of toxicity in both lymphocytes and macrophages.
MATERIALS AND METHODS
Cell culture and analysis for cell cycle and apoptosis. The human leukemic T cell line, Jurkat (E6-1), was maintained in RPMI 1640 medium supplemented with 10% fetal calf serum (FCS), 2 mM glutamine, 10 mM HEPES, 100 U/ml penicillin, and 100 g/ml streptomycin. Cells were harvested in mid-log growth phase and plated at 5 ϫ 10 5 cells/ml in 24-well tissue culture plates. Cells were exposed to medium, CdtA, and CdtC along with wild-type CdtB (CdtB WT ) or CdtB mutants for 18 h (cell cycle) or 48 h (apoptosis). To measure Cdt-induced cell cycle arrest, cells were incubated for the time indicated in the figures and then washed and fixed for 60 min with cold 80% ethanol (28) . The cells were stained with 10 g/ml propidium iodide containing 1 mg/ml RNase (Sigma Chemical) for 30 min. Samples were analyzed on a Becton Dickinson LSRII flow cytometer (BD Biosciences) as previously described (28) . A minimum of 15,000 events were collected for each sample; cell cycle analysis was performed using Modfit (Verity Software House).
DNA fragmentation in Cdt-treated Jurkat cells was employed to determine the percentage of apoptotic cells using a terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) assay (In Situ Cell Death Detection Kit; Boehringer Mannheim, Indianapolis, IN). Jurkat cell cultures were prepared as described above; at the end of the incubation period cells were centrifuged, resuspended in 1 ml of freshly prepared 4% formaldehyde, and vortexed gently. After 30 min at room temperature (RT), the cells were washed with phosphate-buffered saline (PBS) and permeabilized in 0.1% Triton X-100 for 2 min at 4°C. The cells were then washed with PBS and incubated in a solution containing fluorescein isothiocyanate (FITC)-labeled nucleotide and terminal deoxynucleotidyl transferase (TdT) according to the manufacturer's specifications. Following the final wash, the cells were resuspended in PBS and analyzed by flow cytometry.
The human acute monocytic leukemia cell line THP-1 was obtained from ATCC; cells were maintained in RPMI 1640 medium containing 10% fetal bovine serum (FBS), 1 mM sodium pyruvate, 20 M 2-mercaptoethanol, and 2% penicillin-streptomycin at 37°C with 5% CO 2 in a humidified incubator. THP-1 cells were differentiated into macrophages by incubating cells in the presence of 50 ng/ml phorbol myristate acetate (PMA) for 48 h, at which time the cells were washed and incubated for an additional 24 h in medium prior to use.
Construction and expression of plasmid containing CdtB mutant genes. Amino acid substitutions were introduced into the cdtB gene by in vitro site-directed mutagenesis using oligonucleotide primer pairs containing appropriate base changes (Table 1) . Site-directed mutagenesis was performed using a QuikChange II site-directed mutagenesis kit (Stratagene) according to the manufacturer's directions. Amplification of the mutant plasmid was carried out using Pfu Ultra HF DNA polymerase (Stratagene). All mutant constructs utilized pGEMCdtB as a template; construction and characterization of this plasmid were previously described (28) .
In vitro expression of Cdt peptides and CdtB mutants was performed using a rapid translation system (RTS 500 ProteoMaster; Roche Applied Science) as previously described (28) . Reactions were run according to the manufacturer's specifications (Roche Applied Science) using 10 to 15 g of template DNA. After 20 h at 30°C, the reaction mix was removed, and the expressed Cdt peptides were purified by nickel affinity chromatography as described previously (28) . Each CdtB peptide contains a His tag on its C terminus; previous studies have demonstrated that the presence of the His does not interfere with biological activity (24) .
Immunofluorescence and flow cytometry. Jurkat cells or THP-1-derived macrophages (2 ϫ 10 6 ) were incubated for 30 min (surface staining) or 1 h (intracellular staining) in the presence of medium or with 2 g/ml of CdtB WT or mutant in the presence of CdtA and CdtC at 37°C (internalization) or 5°C (surface binding). Surface CdtC was detected by washing cells and exposing them to normal mouse IgG (Zymed Labs; San Francisco, CA); cells were then stained (30 min) for CdtC peptides with anti-CdtC subunit monoclonal antibody (MAb) conjugated to Alexa Fluor 488 (Molecular Probes, Eugene, OR) according to the manufacturer's directions. After cells were washed, they were fixed in 2% paraformaldehyde and analyzed by flow cytometry as previously described (29) . Intracellular CdtB was detected after exposure of cells to toxin (above) and fixation with 2% formaldehyde for 30 min, followed by permeabilization with 0.1% Triton X-100 in 0.1% sodium citrate and staining with antiCdtB MAb conjugated to Alexa Fluor 488 (Molecular Probes).
Measurement of cytokine production. Cytokine production was measured in THP-1-derived macrophages (2 ϫ 10 5 cells) incubated for 5 h. Culture supernatants were collected and analyzed by enzyme-linked immunosorbent assay (ELISA) for interleukin-1␤ (IL-1␤) (Quantikine ELISA kit; R&D Systems) and tumor necrosis factor alpha (TNF-␣; Peprotech) using commercially available kits according to the manufacturers' instructions. In each instance, the amount of cytokine present in the supernatant was determined using a standard curve.
Preparation of LUVs and biolayer interferometry (BLI). Phosphatidylcholine (PC), phosphatidylethanolamine (PE)-biotin, phosphatidylserine (PS), sphingomyelin (SM), and cholesterol were obtained from Avanti Polar Lipids; lipids were stored in chloroform at Ϫ20°C with desiccation. Briefly, large unilamellar vesicles (LUVs) were prepared with a (32, 33) . For some experiments LUV cholesterol was replaced with stigmasterol as described in the figure legends. Lipids were cosolubilized in chloroform and dried under N 2 , and trace amounts of residual solvent were removed under high vacuum. The lipid mixtures were rehydrated at a concentration of 8 mM (total phospholipid) in 20 mM TrisHCl, pH 7.4, containing 50 mM NaCl for 1 h; the suspensions were then vortexed and freeze-thawed in liquid nitrogen, and LUVs were prepared by extrusion by 11 passes through a 100-nm-pore-size membrane (Mini Extruder; Avanti Polar Lipids). BLI analyses were performed using an Octet QK e system (FortéBio) with LUVs comprised of biotinylated PE immobilized on streptavidin sensors in PBS containing 1 mM n-octyl-␤-D-glucopyranoside (OG). Assays were performed in black 96-well plates with a total working volume of 200 l per well at 30°C with an rpm setting of 1,000. Following immobilization of the substrate (LUVs), free streptavidin moieties on the BLI sensors were blocked with biocytin. Measurements of interactions between LUVs and CdtB (and mutants) were performed by incubating the immobilized substrate with various concentrations of CdtB WT (or mutants) in PBS containing 1 mM OG. CdtB was allowed to associate with LUVs for 10 min, followed by a 10-min dissociation in binding buffer alone. After subtraction of the signal from a buffer-alone blank sensor, the data were analyzed using Octet data analysis software using a 1:1 global fit model to calculate the affinity constant (K D ).
Phosphatase assay. Phosphatase activity was assessed by monitoring the dephosphorylation of phosphatidylinositol-3,4,5-triphosphate (PI-3,4,5-P 3 ) as previously described (25, 34) . Briefly, the reaction mixture (20 l) consisted of 100 mM Tris-HCl (pH 8.0), 10 mM dithiothreitol, 0.5 mM diC 16 -phosphatidylserine (Avanti), 25 M PI-3,4,5-P 3 (diC 16 ; Echelon), and the amount of CdtB or mutant as indicated in the figures. Appropriate amounts of lipid solutions were deposited in 1.5-ml tubes, organic solvent was removed, the buffer was added, and a lipid suspension was formed by sonication. Phosphatase assays were carried out at 37°C for 30 min; the reactions were terminated by the addition of 15 l of 100 mM N-ethylmaleimide. Inorganic phosphate levels were then measured using a malachite green assay. Malachite green solution (Biomol Green; Biomol) was added to 100 l of the enzyme reaction mixture, and color was developed for 20 min at RT. Absorbance at 650 nm was measured, and phosphate release was quantified by comparison to inorganic phosphate standards.
Statistical analysis. Means Ϯ standard errors of the means (SEM) were calculated for replicate experiments. Significance was determined using Student's t test; differences between multiple treatments were compared by analysis of variance (ANOVA) paired with Tukey's honestly significant difference (HSD) posttest. A P value of less than 0.05 was considered to be statistically significant.
RESULTS
It is generally accepted that the association of Cdt holotoxin with target cell membranes involves a binding component comprised of the CdtA and CdtC subunits; moreover, this interaction is required for subsequent delivery of the active subunit, CdtB, to intracellular compartments. We have previously demonstrated that the CdtC subunit contains a CRAC region that is involved in CdtC binding to cholesterol within the plasma membrane as well as to model membranes (33) . In addition to CdtC, we have now determined that CdtB also contains a CRAC site, 104 VYIYYSR 110 . The CRAC site conforms to the pattern (L/V)-X 1-5 -Y-X 1-5 -(R/K) in which X [1] [2] [3] [4] [5] represents between one and five residues of any amino acid. Figure 1 shows the position (yellow) of the CdtB CRAC site based upon CdtB's crystal structure; this putative cholesterolbinding region is clearly spatially separated from either of the Cdt binding subunits, CdtA or CdtC. Two edges of the site are exposed to the surface while the middle is buried within the structure, suggesting that it would not be very accessible. While the CRAC site would appear to have minimal access for binding, there is a loop, 81 IQHGGTPI 88 , that is potentially flexible enough to move out of the way and provide access to the CRAC site. Moreover, the hydrophobic stretch of the CRAC site, 104 VYIYY 108 , is compatible with hydrophobic binding that might occur in the context of membrane lipid microdomains. Based upon these molecular models and mutational analysis of critical residues performed on CRAC regions of other proteins, we decided to generate four single-point mutants, CdtB V104P , CdtB Y105P , CdtB Y107P , and CdtB R110P , to enable us to study the contribution of the CRAC region to toxin interaction with model membranes and host cells.
We previously employed surface plasmon resonance (SPR) to assess the role of the CRAC region within the CdtC subunit and its interaction with cholesterol-containing LUVs. In our current study, biolayer interferometry (BLI) was employed to assess the CdtB-associated CRAC region; BLI is a label-free technology that measures molecular interactions in real time for the purpose of detecting and quantifying them and performing kinetic analysis (35) . We initially employed the Cdt holotoxin and compared the affinity constant (K D ) obtained with BLI to that previously determined with SPR. Cholesterol-containing LUVs prepared with PEbiotin were immobilized on streptavidin biosensor plates; Cdt holotoxin (0 to 50 M) was added to the wells, and the association and dissociation between toxin and LUV were determined (see Ϫ6 M, in contrast to the value 3.09 ϫ 10 Ϫ6 M previously determined by SPR (33) . We next assessed the binding of the CdtB subunit by adding various concentrations of CdtB WT (0 to 50 M) to wells. The association and dissociation between toxin and LUV were then measured over a 10-min period. Figure 2A shows a representative series of overlay responses (both real data and modeled data are plotted) for various concentrations of CdtB WT ; based on these responses, the K D was calculated to be 1.37 ϫ 10 Ϫ6 Ϯ 0.2 ϫ 10 Ϫ6 M (Fig. 2E ). Previously, we determined that the CdtC subunit binding to LUV was not only cholesterol dependent but also sterol specific. Therefore, to determine if CdtB exhibits similar properties to CdtC, LUVs were prepared with 20% cholesterol or 20% stigmasterol or without sterol (33) . As shown in Fig. 2D , CdtB WT binding to LUV was sterol dependent and specific; maximum binding to LUV containing cholesterol was 0.24 Ϯ 0.02 nm, a measurement of increased sensor thickness, whereas binding to LUV containing stigmasterol or to LUV prepared without sterol resulted in reduced sensor thickness (binding) (0.12 Ϯ 0.02 nm or 0.04 Ϯ 0.01 nm, respectively).
We next compared the binding affinity of CdtB containing CRAC site mutants to that of the wild-type protein. Three of the mutants, CdtB V104P , CdtB Y105P , and CdtB Y107P , exhibited significantly reduced ability to bind to cholesterol-containing LUVS; the K D for CdtB V104P was determined to be 2.08 ϫ 10 Ϫ5 Ϯ 0.8 ϫ 10
Ϫ5
M; CdtB Y105P and CdtB Y107P binding was too weak, and the K D value could not be calculated even when higher protein concentrations were employed ( Fig. 2B and E) . In contrast to the these three mutants, a fourth CRAC site mutant, CdtB R110P , retained its ability to bind to cholesterol-containing LUVs; this mutant exhib- ited an increase in binding, with a K D of 3.35 ϫ 10 Ϫ8 Ϯ 1.9 ϫ 10 Ϫ8 M ( Fig. 2C and E). It should be noted that changes in the ability of the CdtB mutant proteins to bind to LUVs were not likely due to alterations in structure; circular dichroism (CD) analysis of these proteins failed to demonstrate significant differences among these mutants relative to CdtB WT (see Fig. S2 in the supplemental material).
In previous studies, we demonstrated that Cdt holotoxin binds to target cells with outcomes that are cell type specific. For example, exposure of lymphocytes to Cdt results in cell cycle arrest and apoptosis; in contrast, toxin-treated macrophages derived from either the human THP-1 cell line or monocytes do not become apoptotic but instead are induced to synthesize and secrete proinflammatory cytokines (17, 28, 36) . It should be pointed out that toxin binding to both lymphocytes and macrophages was dependent upon cholesterol and the CRAC region on CdtC. Therefore, we next determined if the CRAC site on CdtB was also important for internalization of this subunit in both lymphocytes and macrophages. Jurkat cells were treated with Cdt subunits as described in Materials and Methods and then permeabilized, stained with anti-CdtB MAb conjugated to Alexa Fluor 488, and analyzed by flow cytometry. Cells treated with subunits CdtA and CdtC as well as untreated cells served as controls and exhibited minimal fluorescence; mean channel fluorescence (MCF) was 5.7 and 7.2, respectively (Fig. 3A) . Intracellular CdtB was detected in cells exposed to CdtB WT in the presence of CdtA and CdtC subunits exhibiting an MCF of 24.9 (Fig. 3B) . The three CdtB CRAC site mutants, CdtB V104P , CdtB Y105P , and CdtB Y107P , which failed to interact with cholesterol-containing LUVs also were unable to enter Jurkat cells; MCF values for these proteins were 4.3, 6.1, and 3.6, respectively ( Fig. 3C to E) . In contrast, cells exposed to the mutant that retained cholesterol-binding capability with LUVs, CdtB R110P , contained detectable protein ( Fig. 3F) (Fig. 5) ; control cells and cells exposed to CdtA and CdtC exhibited background fluorescence of 8.6, whereas cells We have previously demonstrated that non-cholesterol-binding CdtC CRAC site mutants prevent toxin binding to target cells (33) . Therefore, we wanted to determine if, in addition to preventing internalization, the CdtB CRAC site mutants also affected the ability of holotoxin to associate with cells. For these studies, Jurkat cells were treated as described above except that the incubation was performed at 5°C, which we have previously shown blocks CdtB internalization but does not interfere with toxin binding to the cell surface. Cells were then analyzed for the presence of the CdtC subunit on the cell surface as cells were stained without permeabilization. Results are shown in Fig. 6 It is well established that toxin binding and subsequent internalization of CdtB are required for intoxication of cells (37, 38) although the specific intracellular target is somewhat controversial (i.e., nuclear versus cytoplasmic versus membrane). Nonetheless, to corroborate that the three CdtB CRAC site mutants were unable to enter target cells, we next assessed their ability to induce toxicity in both lymphocytes and macrophages. The effect of CdtB mutants on Jurkat cell cycle arrest is shown in Fig. 7 In addition to cell cycle analysis, toxin-treated Jurkat cells were assessed for apoptosis using a TUNEL assay 48 h following exposure to the same protein concentrations utilized for cell cycle analysis. Control cells (medium only) as well as cell cultures exposed to the CdtA and CdtC subunits exhibited only 19% apoptosis. As shown in Fig. 8 , Jurkat cells treated with CdtB WT exhibited dosedependent increases in the percentages of apoptotic cells: 42% Ϯ13.9% with 4 ng/ml CdtB and 53.1% Ϯ 10.2% with 20 ng/ml CdtB. The CRAC site mutant that retained the ability to bind to cholesterol-containing LUVs, CdtB R110P , also retained the ability to induce Jurkat cell apoptosis; exposure to this mutant resulted in 25.6% Ϯ 9.2% (4 ng/ml CdtB R110P ) and 41.6% Ϯ 11.4% (20 ng/ml CdtB R110P ) apoptotic cells. In contrast, treat- Y107P , failed to result in apoptosis. In previous studies, we have identified macrophages as another potential target of Cdt (36) . However, macrophages derived from either human blood monocytes or the monocytic leukemic cell line THP-1 were not susceptible to Cdt-induced apoptosis. Instead, Cdt induced a proinflammatory cytokine response in these cells within 2 h. Moreover, toxin interaction with these cells was shown to be cholesterol dependent as toxin comprised of CdtC containing a CRAC site mutant failed to bind to macrophages and was unable to induce cytokine synthesis and release. Therefore, we also assessed the ability of CdtB-containing CRAC site mutants to induce a proinflammatory cytokine response in THP-1-derived macrophages. As shown in Fig. 9 , treatment of macrophages with CdtB WT resulted in increased release of IL-1␤; control cells produced 24.6 Ϯ 1.3 pg/ml while exposure to 20 ng/ml CdtB resulted in 336.4 Ϯ 29.3 pg/ml IL-1␤. Similar results were obtained for TNF-␣; control cells released 168.2 Ϯ 17.9 pg/ml, and cells exposed to 20 ng/ml CdtB induced the release of 1,676.8 Ϯ 261.0 pg/ml TNF-␣. Treatment of macrophages with CdtB V104P , CdtB Y105P , or CdtB Y107P resulted in a significantly lower cytokine response than that observed with CdtB WT : 83.9 Ϯ 12.0 pg/ml IL-1␤ and 481 Ϯ 125.7 pg/ml TNF-␣ in the presence of CdtB V104P , 86.6 Ϯ 14.7 pg/ml IL-1␤ and 477.1 Ϯ 74.6 pg/ml TNF-␣ in the presence of CdtB Y105P , and 96.2 Ϯ 7.5 pg/ml IL-1␤ and 486.2 Ϯ 88.3 pg/ml TNF-␣ in the presence of CdtB Y107P . Although these values are significantly lower than those observed with CdtB WT , they do represent increases over background levels, suggesting that the mutants retained residual low-level binding. Macrophages exposed to CdtB R110P exhibited a robust dose-dependent cytokine response relative to the other two CdtB mutants but somewhat less than that observed with CdtB WT . CdtB R110P induced the release of 216.0 Ϯ 11.9 pg/ml IL-1␤ and 1,091.4 Ϯ 117.6 pg/ml TNF-␣; these differences were not statistically different from those values obtained with CdtB WT . In previous studies we have demonstrated that Cdt-induced toxicity in lymphocytes (cell cycle arrest and apoptosis) and macrophages (proinflammatory cytokine response) were dependent upon CdtB's ability to function as a PIP 3 phosphatase (25, 36). Therefore, we next confirmed that our observations regarding the loss of toxicity associated with the CdtB CRAC site mutants was not due to altered phosphatase activity. CdtB WT was initially assessed for its ability to dephosphorylate PI-3,4,5-P 3 ; as shown in 
DISCUSSION
It is generally accepted that all three Cdt subunits, CdtA, CdtB, and CdtC, are required to achieve maximal toxic activity, regardless of the target cell. Thus, the holotoxin is believed to function as an AB 2 toxin where the cell binding unit, B, is responsible for toxin binding to the cell surface and thereby delivers the active subunit, A, to intracellular compartments. In the context of Cdt, binding activity is considered to be the result of cooperative activities of both the CdtA and CdtC subunits (reviewed in reference 39). Moreover, it has been proposed that these subunits share structural homology with lectin-like proteins and, further, that fucose moieties might be involved in toxin association with the cell surface (18, 26) . In other studies, glycosphingolipids have been implicated as possible binding sites since inhibitors of glycosphingolipid synthesis reduce toxin intoxication (27) . It should be pointed out that in a more recent study in which Cdts from different microbial species were studied simultaneously, fucosylated structures as well as N-and O-glycans were found not to be required for Cdt-host cell interaction (40) . In contrast, these authors observed that Cdt derived from three sources, A. actinomycetemcomitans, C. jejuni, and H. ducreyi, were each dependent upon membrane cholesterol, thereby confirming the previous observations of BoeszeBattaglia et al. (33) other investigators who have reported that cholesterol depletion failed to alter toxin subunit internalization (41) . It should be noted that this study, by Damek-Poprawa et al., is difficult to assess with respect to the role of cholesterol as the experimental protocol utilized a long exposure time to methyl-␤-cyclodextrin, and, further, cholesterol repletion was not employed to demonstrate specificity.
We have previously demonstrated that the Cdt holotoxin colocalizes on the cell surface with the ganglioside GM1 in the context of cholesterol-rich membrane microdomains, or lipid rafts (29) . Furthermore, disruption of lipid rafts by cholesterol depletion reduced toxin binding, CdtB internalization, and cell susceptibility to Cdt intoxication (33) . We have also demonstrated cholesterol-specific binding of Cdt to both model membranes and lymphocyte membranes; furthermore, this binding is dependent upon a cholesterol recognition sequence within the CdtC subunit. In this regard, numerous proteins have been shown to bind cholesterol; these include the benzodiazepine receptor, the HIV transmembrane protein gp41, caveolin, G protein-coupled receptors, components of Ca ϩϩ -and voltage-gated K ϩ channels, apolipoproteins, the translocator protein TSPO, and, more recently, the leukotoxin produced by A. actinomycetemcomitans (42) (43) (44) (45) (46) (47) (48) (49) (50) . Each of these cholesterol-binding proteins contains a CRAC sequence, L/V-X 1-5 -Y-X 1-5 -R/K, where X 1-5 represents one to five residues of any amino acid. Indeed, we have shown that the CdtC subunit of the A. actinomycetemcomitans Cdt also contains such a CRAC site, with the sequence 68 LIDYKGK 74 . Mutation of residues within this region reduced toxin binding to LUVs and cells, CdtB internalization, and toxicity. In the current study, we have analyzed the active subunit of the A. actinomycetemcomitans Cdt, CdtB, for its ability to bind to LUVs containing cholesterol. Indeed, CdtB WT demonstrated high affinity for cholesterol-containing LUVs, and binding was significantly reduced when LUVs either did not contain any sterol or when stigmasterol was utilized as a substitute for cholesterol. These observations led us to consider the possibility that, like CdtC, CdtB also might contain a CRAC site; indeed motif analysis of CdtB confirmed the presence of the CRAC site 104 VYIYYSR 110 . In order to study the requirement for the CdtB CRAC site in binding to LUVs and cells, we mutated four residues within this site ( 104 VYIYYSR 110 ; mutations are shown in bold); we predicted that three of these would be critical to its binding function. First, CdtB V104P and CdtB Y107P were selected because they represent critical residues within the CRAC motif. Also, they are very well conserved in all CdtB proteins with the exception that CdtB V104 is not conserved in toxin from bacteria that are facultative intracellular pathogens, such as Salmonella. Thus, Salmonella-derived CdtB most likely utilizes a different pathway to reach its intracellular target than that used by CdtB produced by bacteria that are associated with extracellular infection, such as A. actinomycetemcomitans. This raises the likelihood that CdtB V104P is a critical residue for cholesterol interaction since it is unlikely that the Salmonella-derived toxin is dependent upon a pathway that has a requirement for binding to plasma membrane cholesterol. Second, CdtB Y105P and CdtB Y107P were selected as they are among the most conserved residues in the entire CRAC site, and, therefore, there was a high likelihood that they would be critical to the function of the CRAC site. Finally, CdtB R110P was selected as this is the least conserved CRAC site residue among the CdtB proteins. In fact, several CdtB proteins from Helicobacter species have a proline conserved at this position instead of arginine. Therefore, we expected not only that this residue was not critical to CRAC site function but also that the proline substitution would also not contribute to any change in cholesterol binding. Thus, CdtB mutation of the CRAC region within CdtC (33) and with those of other investigators who made similar CRAC site mutations of residues within the CdtC subunit of Cdts produced by other bacterial species as well as to other cholesterol-binding proteins (30, 31, 42, 50) . In each instance CRAC site mutations resulted in a loss of cholesterol binding and associated downstream biological effects; in contrast, CdtB R110P had no effect on Cdt binding and CdtB internalization, confirming our expectation for the relative role of each of these residues within the CRAC site and overall role in the CdtB-cholesterol interaction. It should be noted that we do not have a clear explanation for the observed increase in affinity for this mutant.
The CRAC domain is a short linear motif that proceeds from the N terminus to the C terminus and represents the most popular cholesterol-binding domain. More recently, Baier et al. (51) identified another cholesterol-binding motif, CARC, with a sequence similar to that of the CRAC domain but oriented along the polypeptide chain in the opposite direction. CARC constitutes an in-
, from the N terminus to the C terminus. Interestingly, we found that a CARC site exists in CdtB and is embedded within the CRAC site (shown in bold), with the sequence 100 RPNMVYIYYSRL 111 . While we cannot entirely exclude the possibility that the CARC motif may also contribute to CdtB-cholesterol binding, we believe that the analysis of the CRAC site mutants is more consistent with a functional role for the CRAC motif. Furthermore, CdtB R100 is only moderately conserved among CdtB proteins.
The location of the CRAC site based upon molecular models of the crystal structure of CdtB indicates that the region has two exposed edges and a buried middle region. Our mutation analysis suggests that the lower region ( Fig. 1) and buried middle region are critical to binding. These results would suggest that the structure of CdtB and the availability of the CRAC site are likely altered in the context of lipid rafts as opposed to the rigid crystal structure.
It should also be noted that in previous studies we demonstrated that depletion of cholesterol from lymphocyte membranes reduced Cdt holotoxin binding, CdtB internalization, and toxicity (33) . Likewise, repletion studies in which membrane cholesterol was restored also resulted in reestablishment of toxin binding, CdtB internalization, and susceptibility to Cdt intoxication. We initially interpreted these results as evidence for the role of cholesterol and the CdtC CRAC site in toxin-cell interactions; however, it should now be noted that these observations are also consistent with our current findings for a critical role for cholesterol and the CdtB CRAC site as well.
Finally, we assessed the CdtB CRAC site mutants for their ability to intoxicate cells. For these studies we employed two host target cells: lymphocyte and macrophages. Jurkat cells treated with the three CdtB cholesterol-binding-defective mutants, CdtB V104P , CdtB Y105P , and CdtB Y107P , also exhibited reduced toxicity, which was reflected in fewer cells in G 2 arrest at 18 h and fewer apoptotic cells at 48 h than amounts with CdtB WT . Likewise, the proinflammatory cytokine response that is induced in macrophages treated with wild-type toxin was reduced in cells treated with the defective cholesterol-binding mutants; this was reflected in reduced secretion of both IL-1␤ and TNF-␣. The fourth CRAC site mutant, CdtB R110P , was unaltered in its ability to bind to cholesterol-containing LUVs and to deliver CdtB to intracellular compartments in both Jurkat cells and macrophages. Likewise, the CdtB R110P mutant exhibited toxic activity comparable to that of CdtB WT as it induced both G 2 arrest and apoptosis in lymphocytes and cytokine release in macrophages. While CdtB R110P was able to bind, internalize, and intoxicate cells, it did so at levels less than those observed with CdtB WT although these differences were not statistically significant.
In previous studies we demonstrated that toxic effects of Cdt on both lymphocytes and macrophages were dependent upon the ability of CdtB to function as a phosphatidylinositol-3,4,5-triphosphate phosphatase (25, 36) . Thus, we also assessed the CdtB mutants for lipid phosphatase activity; indeed, all four CdtB CRAC site mutants retained enzymatic activity at levels comparable to those of the wild-type protein. This finding provides further evidence that reduced toxicity associated with these mutants is the result of changes in cell binding and internalization rather than of altered structure and/or the molecular mode of action associated with the active subunit; lack of altered structure was confirmed by CD analysis.
Collectively, our current findings, along with previous observations, provide strong support for the notion that Cdt association with target cells is dependent upon the ability of both the CdtC and CdtB subunits to bind to cholesterol. Furthermore, our observations demonstrate that Cdt-host cell association involves membrane microdomains enriched in cholesterol and is dependent upon the integrity of these so-called lipid rafts. Lipid rafts represent liquid-ordered microdomains which are distributed in the plasma membrane and whose lipid composition and high cholesterol content differ from the those of the rest of the membrane (52) . Generally, lipid rafts are regarded as scaffolds for a number of molecular entities, which include ion channels, receptors, and signaling platforms; thus, these membrane regions provide an ideal structure to facilitate communication of extracellular stimuli to the intracellular milieu, leading to signaling events that regulate cell growth, proliferation, and survival (53, 54) .
It is becoming increasingly evident that membrane rafts facil- itate target cell interaction with several microbial toxins (55, 56) ; in addition to binding and clustering, these interactions may contribute to toxin internalization and/or a molecular mode of action. For instance, lipid membrane rafts may provide a mechanism by which receptors are concentrated and thereby promote ligand or pathogen binding. One such example is cholera toxin, which is pentameric and binds to targets cells via the ganglioside GM1. It is likely that cholera toxin simultaneously binds with high affinity to multiple receptors as a result of receptor concentration within the raft (56, 57) . Likewise, the pore-forming leukotoxin from A. actinomycetemcomitans recognizes cholesterol via a CRAC site, which facilitates clustering to its receptor in the context of lipid rafts (50) . Another pore-forming toxin, the aerolysin from Aeromonas hydrophila, which binds to glycosylphosphatidylinositol (GPI)-anchored proteins, also utilizes the concentrating properties of rafts to facilitate oligomerization, a requisite for channel formation (56, 58) . These findings are consistent with the high cholesterol content of lipid rafts, which we propose facilitate Cdt binding as well.
Association with lipid rafts may also provide access to endocytic processes and intracellular trafficking routes. For example, Shiga toxin and cholera toxin bind to glycosphingolipids, which results in lipid clustering and changes in membrane properties that facilitate internalization and endocytic uptake (59) . Likewise, several pathogens enter host cells in a cholesterol-dependent manner (55, 56) ; for example, the uptake of E. coli strains which express FimH has been shown to involve cholesterol-rich rafts. Similarly, Shigella invades cells via interaction between the invasin, IpaB, and the raft-associated receptor CD44 (60) . Several enveloped and nonenveloped viruses (for example, simian virus 40 [SV40], HIV, and herpes simplex virus [HSV]) also require lipid rafts for binding or entry by endocytosis (60) . It is interesting that Cdt associates with cholesterol in the context of lipid rafts; several investigators have also demonstrated that CdtB is internalized by endocytic mechanisms, and in the case of H. ducreyi Cdt, this appears to be dynamin dependent (38) . This last observation is critical as disruption of the cholesterol-binding CRAC region for baculovirus has also been shown to compromise dynamin-dependent viral endocytosis (61) .
In conclusion, we propose that binding of cholesterol by the CRAC regions contained within the CdtC and CdtB subunits results in the association of the Cdt holotoxin with membrane lipid rafts. It is likely that lipid raft association is critical for not only holotoxin binding but also the internalization and, possibly, the function of the active subunit, CdtB. These studies predict that cholesterol disposition within the membrane influences binding of CdtC and CdtB to the cell surface; therefore, we propose that Cdt favors raft-associated cholesterol, resulting in localized toxinrich regions. This association may also be critical to the mode of action of the toxin, thereby allowing it to hijack lipid raft-associated signaling platform(s) and, perhaps, provide access to intracellular pools of PI-3,4,5-P 3 . Furthermore, perturbation of signaling cascades likely contributes to cell cycle arrest and eventual cell death in lymphocytes; similar events likely contribute to the toxininduced proinflammatory cytokine response in macrophages as well. While these studies do not exclude the possibility of the existence of additional receptors that might be recognized by CdtA, they do clearly demonstrate that cholesterol recognition via CRAC sites and mutation of these regions are sufficient to block Cdt-mediated toxicity in target cells.
